Eiger BioPharmaceuticals (EIGR)
(Delayed Data from NSDQ)
$5.01 USD
+0.03 (0.50%)
Updated Mar 28, 2024 03:50 PM ET
After-Market: $5.06 +0.06 (1.10%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
EIGR 5.01 +0.03(0.50%)
Will EIGR be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for EIGR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EIGR
Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
EIGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates
Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?
Other News for EIGR
12 Health Care Stocks Moving In Thursday's Intraday Session
Christine Murray Resigns from Eiger Biopharmaceuticals Board
Eiger BioPharmaceuticals trading resumes
Eiger BioPharmaceuticals trading halted, volatility trading pause
Celcuity appoints Mayer as Chief Commercial Officer